You can buy or sell ViewRay and other stocks, options, ETFs, and crypto commission-free!
ViewRay, Inc. engages in the design, manufacture and market magnetic resonance imaging (MRI) system. It develops MRIdian to address the key limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. Read More The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.
Oakwood Village, Ohio
52 Week High
52 Week Low
Simply Wall StMar 20
Are ViewRay, Inc. (NASDAQ:VRAY) Shareholders Getting A Good Deal?
Two important questions to ask before you buy ViewRay, Inc. (NASDAQ:VRAY) is, how it makes money and how it spends its cash. After investment, what’s left over is what belongs to you, the investor. This also determines how much the stock is worth. I’ve analysed below, the health and outlook of ViewRay’s cash flow, which will help you understand the stock from a cash standpoint. Cash is an important concept to grasp as an investor, as it directly impacts the value of your shares and the future growth potenti...
The Motley FoolMar 15
ViewRay, Inc. (VRAY) Q4 2018 Earnings Conference Call Transcript
ViewRay, Inc. (NASDAQ:VRAY) Q4 2018 Earnings Conference Call March 14, 2019 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the fourth-quarter 2018 ViewRay earnings conference call. [Operator instructions] As a reminder, this call is being recorded. I would now like to introduce your host for today's conference, Ms. Michaella Gallina, senior director of investor relations. You may begin. Micha...
Yahoo FinanceMar 14
ViewRay: 4Q Earnings Snapshot
OAKWOOD VILLAGE, Ohio (AP) _ ViewRay Inc. (VRAY) on Thursday reported a loss of $16.7 million in its fourth quarter. The Oakwood Village, Ohio-based company said it had a loss of 17 cents per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 22 cents per share. The radiation therapy systems maker posted revenue of $20.7 million in the period. For the year, the company reported that its loss widened to $76.4 mi...
-$0.23 per share
-$0.17 per share